Impact of China’s National Volume-Based Drug Procurement: A Multilevel Interrupted Time Series Analysis on Medical Expenditures in Hypertensive Patients

Document Type : Original Article

Authors

• Yunxiang Huang ^{1, 2, 3 ¶}
• Yan Ren ^{1, 2, 3 ¶}
• Yuanjin Zhang ^{1, 2, 3}
• Yulong Jia ^{1, 2, 3}
• Qianrui Li ⁴
• Minghong Yao ^{1, 2, 3}
• Yuning Wang ^{1, 2, 3}
• Fan Mei ^{1, 2, 3}
• Kang Zou ^{1, 2, 3}
• Huangang Hu ⁵
• Jing Tan ^{1, 2, 3}
• Xin Sun ^{1, 2, 3, 6}

¹ Institute of Integrated Traditional Chinese and Western Medicine, and Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu, China

² NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, Chengdu, China

³ Sichuan Center of Technology Innovation for Real World Data, Chengdu, China

⁴ Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, China

⁵ Tianjin Health Care Big Data Ltd, Tianjin, China

⁶ Department of epidemiology and Biostatistics, West China School of Public Health, Sichuan University, Chengdu, China

Abstract

Keywords

• Centralized Drug Procurement
• Volume-Based Procurement
• China
• Policy Effectiveness Evaluation
• Interrupted Time Series Analysis
• Multilevel Model